AU4812697A - Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors - Google Patents

Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors

Info

Publication number
AU4812697A
AU4812697A AU48126/97A AU4812697A AU4812697A AU 4812697 A AU4812697 A AU 4812697A AU 48126/97 A AU48126/97 A AU 48126/97A AU 4812697 A AU4812697 A AU 4812697A AU 4812697 A AU4812697 A AU 4812697A
Authority
AU
Australia
Prior art keywords
matrix metalloproteinase
alpha
metalloproteinase inhibitors
hydroxamic acids
amino sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU48126/97A
Other languages
English (en)
Inventor
E. Jon Jacobsen
Mark A. Mitchell
Martha A. Warpehoski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU4812697A publication Critical patent/AU4812697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU48126/97A 1996-10-22 1997-10-20 Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors Abandoned AU4812697A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2958596P 1996-10-22 1996-10-22
US60029585 1996-10-22
PCT/US1997/018235 WO1998017645A1 (en) 1996-10-22 1997-10-20 α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Publications (1)

Publication Number Publication Date
AU4812697A true AU4812697A (en) 1998-05-15

Family

ID=21849807

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48126/97A Abandoned AU4812697A (en) 1996-10-22 1997-10-20 Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors

Country Status (9)

Country Link
US (1) US5804593A (enExample)
EP (1) EP0934267B1 (enExample)
JP (1) JP2001503400A (enExample)
AT (1) ATE212619T1 (enExample)
AU (1) AU4812697A (enExample)
CA (1) CA2268418A1 (enExample)
DE (1) DE69710204T2 (enExample)
ES (1) ES2171905T3 (enExample)
WO (1) WO1998017645A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
HUP0000852A2 (hu) * 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
CN1265647A (zh) 1997-07-31 2000-09-06 普罗克特和甘保尔公司 无环金属蛋白酶抑制剂
WO2000037433A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6753337B2 (en) * 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6946473B2 (en) * 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
SK12462001A3 (sk) 1999-03-03 2002-04-04 The Procter & Gamble Company Inhibítory metaloproteáz
KR20010102486A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2005507937A (ja) * 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
JP4002927B2 (ja) * 2002-05-29 2007-11-07 メルク エンド カムパニー インコーポレーテッド 炭疸病治療および致死因子阻害に有用な化合物
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US7199155B2 (en) * 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
EP1599449A2 (en) * 2003-02-25 2005-11-30 TopoTarget UK Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
CA2566191A1 (en) * 2004-05-11 2005-12-15 Merck & Co., Inc. Process for making n-sulfonated-amino acid derivatives
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
WO2019102488A1 (en) 2017-11-27 2019-05-31 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors
WO2026015506A1 (en) * 2024-07-11 2026-01-15 Purdue Research Foundation Dual inhibitors for hdac3 and hiv-1 pr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
AU690703B2 (en) * 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
EP0800449B1 (de) * 1995-01-03 1999-07-07 Reinhard Eichenberger Verfahren und vorrichtung zur herstellung von verstärkungseinlagen für werkstoffverbunde, insbesondere schleif- oder trennscheiben
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
ES2185750T3 (es) * 1995-08-08 2003-05-01 Ono Pharmaceutical Co Derivados de acido hidroxamico utiles para la inhibicion gelatinasa.
TR199800849T2 (xx) * 1995-11-13 1998-07-21 Hoechst Aktiengesellschaft Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
NZ325939A (en) * 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives

Also Published As

Publication number Publication date
ATE212619T1 (de) 2002-02-15
WO1998017645A1 (en) 1998-04-30
EP0934267B1 (en) 2002-01-30
JP2001503400A (ja) 2001-03-13
CA2268418A1 (en) 1998-04-30
DE69710204D1 (en) 2002-03-14
US5804593A (en) 1998-09-08
DE69710204T2 (de) 2002-10-24
ES2171905T3 (es) 2002-09-16
EP0934267A1 (en) 1999-08-11

Similar Documents

Publication Publication Date Title
DE69710204D1 (en) Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
DE69809187D1 (de) Metalloproteinase-Inhibitoren
AU1319597A (en) Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
ATE165817T1 (de) Metalloproteinaseinhibitoren
NO972393D0 (no) Nye benzylpyrimidiner
GB2303850A (en) Metalloproteinase inhibitors
YU17092A (sh) Derivati 2,4-diaminohinazolina
CA2242416A1 (en) Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
EA200300067A1 (ru) Кристаллическая форма целекоксиба
NO20002505D0 (no) <Alfa>-hydroksy, -amin og fluorderivater av <beta>- sulfonylhydroksamsyrer som matriks metallproteinaseinhibitorer
AU8350698A (en) Metalloproteinase inhibitors
EA199800189A1 (ru) Оптически активное производное фенилпиримидина в качестве анальгетика
NO973752D0 (no) 1<alfa>-2-(4-nitrofenyl sulfonyl)etoksykarbonylaminosyrer
NO308249B1 (no) Nye indan-2-mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase
NO305755B1 (no) Nye aryloksymetyloksazoliner og farmas°ytiske preparater inneholdende dem
EA199900809A1 (ru) Производные 2-(замещенный бензоил) циклоакил-1-карбоновой кислоты
SV1998000088A (es) Compuestos farmaceuticos
AU5230898A (en) Metalloproteinase inhibitors
TR199902584T2 (xx) Yeni bir proses.
YU200791A (sh) Trifluorometil 1-karba (1-detia) cefemi
AU538931B2 (en) (n-thenyl-2-methyl) amino-2-imidazoline
CO5640139A2 (es) Nuevos antibioticos macrolidos semisinteticos de la serie de azalidas
EA200200416A1 (ru) Кристаллы ингибитора натрий-водородного обмена 1 типа
ES8504754A1 (es) Procedimiento para preparar la n-(3-trifluorometil fenil)-n-propargil-piperazina.
CA2258960A1 (en) A process for preparing naphthyridones and intermediates